Cubist Announces FDA Accepts Tedizolid NDA with Priority Review
December 30, 2013 at 07:36 AM EST
Cubist Pharmaceuticals (NASDAQ: CBST ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for its investigational antibiotic tedizolid
